The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Open accessAbstract
BACKGROUND: The extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving first-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in the phase 3 CheckMate 214 trial. Survival, response, and safety outcomes with NIVO+IPI versus SUN were assessed after a minimum of 42 months of follow-up. METHODS: Patients with aRCC were enrolled from October 16, 2014, through February 23, 2016. Patients stratified by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk and region were randomized to nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for four doses, followed by nivolumab (3 mg/kg) every 2 weeks; or SUN (50 mg) once per day for 4 weeks (6-week cycle). Primary endpoints: overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) per independent radiology review committee in IMDC intermediate-risk/poor-risk patients. Secondary endpoints: OS, PFS, and ORR in the intention-to-treat (ITT) population and safety. Favorable-risk patient outcomes were exploratory. RESULTS: Among ITT patients, 550 were randomized to NIVO+IPI (425 intermediate/poor risk; 125 favorable risk) and 546 to SUN (422 intermediate/poor risk; 124 favorable risk). Among intermediate-risk/poor-risk patients, OS (HR, 0.66; 95% CI, 0.55-0.80) and PFS (HR, 0.75; 95% CI, 0.62-0.90) benefits were observed, and ORR was higher (42.1% vs 26.3%) with NIVO+IPI versus SUN. In ITT patients, both OS benefits (HR, 0.72; 95% CI, 0.61-0.86) and higher ORR (39.1% vs 32.6%) were observed with NIVO+IPI versus SUN. In favorable-risk patients, HR for death was 1.19 (95% CI, 0.77-1.85) and ORR was 28.8% with NIVO+IPI versus 54.0% with SUN. Duration of response was longer (HR, 0.46-0.54), and more patients achieved complete response (10.1%-12.8% vs 1.4%-5.6%) with NIVO+IPI versus SUN regardless of risk group. The incidence of treatment-related adverse events was consistent with previous reports. CONCLUSIONS: NIVO+IPI led to improved efficacy outcomes versus SUN in both intermediate-risk/poor-risk and ITT patients that were maintained through 42 months' minimum follow-up. A complete response rate >10% was achieved with NIVO+IPI regardless of risk category, with no new safety signals detected in either arm. These results support NIVO+IPI as a first-line treatment option with the potential for durable response. TRIAL REGISTRATION NUMBER: NCT02231749.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Long-term follow-up has demonstrated durable survival benefi t for a subset of patients with melanoma and RCC, and combination therapy with ICT is under active investigation for a number of tumor types ( 55,58 ).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationPembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Self-citationAssociation of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R., Kaneda, H., Hasegawa, Y., Tanaka, K., Takeda, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2925 · Cited by 1,003
Motzer, R. J., Rini, B. I., McDermott, D. F., Arén Frontera, O., Hammers, H. J., Carducci, M. A., Salman, P., Escudier, B., Beuselinck, B., Amin, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30413-9 · Cited by 775
Self-citationPembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Sanlorenzo, M., Vujic, I., Daud, A., Algazi, A., Gubens, M., Luna, S. A., Lin, K., Quaglino, P., Rappersberger, K., & Ortiz-Urda, S. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.1916 · Cited by 449
Atkins, M. B., & Tannir, N. M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.009 · Cited by 392
Self-citation
Cited by
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026982 · Cited by 1,791
Self-citationThe Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Albiges, L., Tannir, N. M., Burotto, M., McDermott, D., Plimack, E. R., Barthélémy, P., Porta, C., Powles, T., Donskov, F., George, S., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-001079 · Cited by 519
Self-citationBeyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00455-z · Cited by 356
Self-citationManagement of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
Rathmell, W. K., Rumble, R. B., Van Veldhuizen, P. J., Al-Ahmadie, H., Emamekhoo, H., Hauke, R. J., Louie, A. V., Milowsky, M. I., Molina, A. M., Rose, T. L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00868 · Cited by 336
Metadata
- Authors
- Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., George, S., Grünwald, V., Porta, C., Neiman, V., Ravaud, A., Choueiri, T. K., Rini, B. I., Salman, P., Kollmannsberger, C. K., Tykodi, S. S., Grimm, M.-O., Gurney, H., Leibowitz-Amit, R., Geertsen, P. F., Amin, A., Tomita, Y., McHenry, M. B., Saggi, S. S., & Tannir, N. M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Institut Gustave Roussy (FR)
- Beth Israel Deaconess Medical Center (US)
- Centro de Investigación Clínica Bradford Hill, Santiago, Chile
- University Hospital Olomouc (CZ)
- National Health Service (GB)
- Aarhus University Hospital (DK)
- Fox Chase Cancer Center (US)
- Institut de Cancérologie Strasbourg (FR)
- The University of Texas Southwestern Medical Center (US)
- Roswell Park Comprehensive Cancer Center (US)
- Essen University Hospital (DE)
- University of Pavia (IT)
- Tel Aviv University (IL)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Dana-Farber Cancer Institute (US)
- Cleveland Clinic (US)
- Fundación Arturo López Pérez (CL)
- BC Cancer Agency (CA)
- University of Washington (US)
- Jena University Hospital (DE)
- Westmead Hospital (AU)
- Oncology Institute, Shamir Medical Center, Be'er Yaakov, Israel
- Herlev Hospital (DK)
- Levine Cancer Institute (US)
- Niigata University (JP)
- Bristol-Myers Squibb (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Motzer, Robert J
- ORCID
- Motzer, Robert J
- Escudier, Bernard
- McDermott, David F
- Melichar, Bohuslav
- Powles, Thomas
- Donskov, Frede
- Plimack, Elizabeth R
- Barthélémy, Philippe
- Hammers, Hans J
- George, Saby
- Grünwald, Viktor
- Porta, Camillo
- Ravaud, Alain
- Choueiri, Toni K
- Rini, Brian I
- Salman, Pamela
- Kollmannsberger, Christian K
- Tykodi, Scott S
- Grimm, Marc-Oliver
- Gurney, Howard
- Geertsen, Poul F
- Amin, Asim
- Tomita, Yoshihiko
- McHenry, M Brent
- Tannir, Nizar M
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2020-07
- Volume
- 8
- Issue
- 2
- Pages
- e000891
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC7359377
- OpenAlex
- W3042095160
- Cited by
- 224
- References
- 18
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 27 · 2023: 43 · 2022: 57 · 2021: 58 · 2020: 18
- FWCI
- 24.77
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-05-03)
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Funders
- Bristol Myers Squibb and ONO Pharmaceutical Company Limited
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- advanced renal cell carcinoma, nivolumab, ipilimumab, sunitinib, immune checkpoint inhibitors, first-line therapy, overall survival, progression-free survival, objective response rate, long-term follow-up, IMDC risk stratification, treatment safety, immune-related adverse events, CheckMate 214, combination immunotherapy, tyrosine kinase inhibitors
- MeSH terms
- Ipilimumab, Sunitinib, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Follow-Up Studies, Humans, Kidney Neoplasms, Male, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. https://app.cochat.ai/papers/10.1136/jitc-2020-000891
- The paper
- Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., George, S., Grünwald, V., Porta, C., Neiman, V., Ravaud, A., Choueiri, T. K., Rini, B. I., Salman, P., Kollmannsberger, C. K., . . . Tannir, N. M. (2020). Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-000891
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.